Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFORM: Phase 1 Study of ATG-031 in Advanced Solid Tumors or B-NHL
NCT06028373Phase 1Terminated
- Sponsor
- Antengene
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atg-031 in solid tumor and B-cell non-Hodgkin lymphoma (8 arms), sponsored by Antengene. Primary endpoints: Adverse Events at 90 days, Dose-Limiting Toxicity at 42 days and 1 more. Started Dec 2023; status: terminated.
02
Drugs
atg-031
03
Conditions
solid tumorB-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06028373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028373.